EUVIMEDEUVIMED entdecken
Crossref

Creatinine/cystatin C ratio‐guided selection of renal function marker in sarcopenia

Rina Kamiya, Ryota Tanaka iD, Haruka Tsushita, Ryosuke Tatsuta iD, Naoki Yoshikawa, Hiroki Itoh

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Rina Kamiya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan. Hauptthemen laut MEDLINE: Sarcopenia, Cystatin C, Creatinine. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The serum creatinine–to–cystatin C ratio (Cr/Cys‐C) has recently garnered interest as a simpler surrogate marker for sarcopenia assessment. However, the reported Cr/Cys‐C thresholds vary in different disease states, and Cr/Cys‐C is yet to be established as a reliable diagnostic marker. This study aimed to identify a Cr/Cys‐C threshold at which Cys‐C–based estimated glomerular filtration rate (eGFRcys) provides more accurate renal function assessment than Cr–based eGFR (eGFRcr) for informing drug dosing strategies in sarcopenia.

Methods

This retrospective study included 172 patients who had been receiving a consistent dose of oral magnesium oxide for at least one week and had undergone same‐day measurements of serum Cr, Cys‐C and magnesium (Mg). Based on previously reported Cr/Cys‐C thresholds (< 0.887, < 0.80 and < 0.67), patients were stratified into sarcopenia and non‐sarcopenia cohorts.

Results

In all subjects, eGFRcr and eGFRcys each demonstrated a significant negative correlation with serum Mg level. At Cr/Cys‐C thresholds of < 0.80 and < 0.67, serum Mg level showed a significant inverse correlation with eGFRcys in both sarcopenia and non‐sarcopenia cohorts, but did not correlate significantly with eGFRcr in the sarcopenia cohort. ROC analysis identified an optimal Cr/Cys‐C cutoff of 0.82 at which serum Mg level correlates significantly with eGFRcys but not with eGFRcr, yielding a sensitivity of 100% and specificity of 69.23%.

Conclusion

These findings suggest that at Cr/Cys‐C below 0.82, the accuracy of eGFRcr in assessing renal function may be compromised, and eGFRcys should be used in such cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaCystatin CCreatinineHumansFemaleGlomerular Filtration RateRetrospective StudiesMaleBiomarkersAgedMiddle AgedMagnesiumMagnesium OxideAged, 80 and overKidney Function Tests

Stichwörter der Autor:innen

creatininecystatin‐Cmagnesiumrenal functionsarcopenia

Substanzen

Cystatin CCreatinineBiomarkersMagnesiumMagnesium Oxide

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.

ORCID-Profile: Ryota Tanaka, Ryosuke Tatsuta

Zitieren

APA

Kamiya, R., Tanaka, R., Tsushita, H., Tatsuta, R., Yoshikawa, N., & Itoh, H. (2026). Creatinine/cystatin C ratio‐guided selection of renal function marker in sarcopenia. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70469

Vancouver

Kamiya R, Tanaka R, Tsushita H, Tatsuta R, Yoshikawa N, Itoh H. Creatinine/cystatin C ratio‐guided selection of renal function marker in sarcopenia. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70469

BibTeX
@article{Kamiya2026,
  author = {Kamiya, Rina and Tanaka, Ryota and Tsushita, Haruka and Tatsuta, Ryosuke and Yoshikawa, Naoki and Itoh, Hiroki},
  title = {Creatinine/cystatin C ratio‐guided selection of renal function marker in sarcopenia},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70469}
}
Kostenlos starten →